A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses ...

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry Provided by Business Wire Aug 5, 2025, 5:00:00 AM ...

Q2 2025 Management View Shantanu K. Gaur, CEO, stated that "our new strategy doubles down on metabolically healthy weight loss, losing weight, keeping it off and maintaining muscle mass, with a ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

In my opinion, combination therapy is here to stay, and has its own niche in the treatment of symptomatic BPH. CLICK HERE for subscription information about this journal.